ABSTRACT

The restriction of energy intake has documented beneficial effects on numerous diseases including cancer, yet the mechanism(s) that accounts for these effects is unknown. Recently, we showed that the inhibitory activity against mammary carcinogenesis mediated by energy restriction (ER) is accompanied by an increase in the secretion of adrenal cortical steroids. However, ER caused a concomitant reduction in circulating levels of insulin-like growth factor-1, which also may be involved in inhibiting carcinogenesis. To determine what cellular and molecular effects may be because of corticosterone per se, detailed mechanistic studies were performed in vitro using a mouse mammary hyperplastic cell line (TM10). The following questions were addressed: (a) is corticosterone-mediated growth inhibition accounted for by disruption of cell cycle machinery; (b) is growth inhibition accompanied by the induction of apoptosis; and (c) is growth inhibition irreversible? At doses of corticosterone (50–200 μM) for 24–72 h that resulted in inhibition (up to 76%; \(P < 0.001\)) of growth, a dose- and time-dependent G1 arrest in cell cycle progression was observed. In the studies analyzing cell cycle regulatory molecules, corticosterone treatment of cells resulted in a strong induction (up to 10-fold over control; \(P < 0.01\)) of KIP1/P27 together with a decrease (up to 98%; \(P < 0.01\)) in cyclin-dependent kinase 4 (CDK4) and cyclin D1 protein levels. Cells treated with corticosterone also showed an increased binding (up to 2.6-fold over control; \(P < 0.01\)) of KIP1/P27 with CDK4, together with a strong increase (up to 89%; \(P < 0.01\)) in the kinase activity of the CDK4-cyclin D1 complex. Treatment of cells with KIP1/P27 antisense oligonucleotides reversed the growth inhibitory effects of corticosterone. Treatment of cells with RU 486, a glucocorticoid receptor blocker, reversed the effects of corticosterone on cell growth and KIP27 protein levels suggesting the involvement of the glucocorticoid receptor in accounting for these effects. Additional studies assessing the biological fate of cells after corticosterone treatment showed that corticosterone exerted reversible growth inhibitory effects with limited apoptotic cell death. Together, these findings show a reversible cytostatic effect of corticosterone via perturbations in cell cycle regulators causing a G1 arrest in the absence of increased levels of apoptosis. These data provide evidence for a role of corticosterone on some but not all of the cellular activities associated with ER-mediated inhibition of mammary carcinogenesis.

INTRODUCTION

ER\(^3\) has been shown to exert profound inhibitory effects on carcinogenesis at several organ sites including mammary gland, colon, liver, and skin (1–4). An accumulating amount of evidence points to a specific effect of ER on various growth factors, oncogenes, and tumor suppressor genes that are involved in the carcinogenic process (1, 5–8). ER has been shown to decrease cell proliferation and increase apoptotic cell death (9, 10). Recent studies have also documented an effect of ER on KIP1/P27 induction and a decrease in cyclin D1 expression in mammary tumors (11). Likewise, dietary feeding of corticosterone was able to increase KIP1/P27 expression in mammary epithelial cells in rats suggesting that ER leads to an increased level of cortical steroid that alters cell cycle machinery in mammary epithelium resulting in an inhibition of mammary carcinogenesis (12). Indeed, our recent studies have shown that urinary levels of immunoreactive cortical steroids were directly related to the inhibition of mammary carcinogenesis by ER (1) and that the dietary administration of corticosterone to ad libitum fed, adrenal intact animals also inhibited mammary carcinogenesis.\(^4\) Nonetheless, we have shown recently that coincident with the up-regulation of cortical steroid levels in plasma, ER causes a reduction in circulating levels of IGF-1,\(^5\) an effect also observed in animals administered supplemental dietary corticosterone.\(^4\) Hence, in vivo it is likely that it will be difficult to dissociate the effect of increased levels of corticosterone per se from effects exerted on other hormones such as IGF-1. This situation prompted the use of an in vitro model to complement in vivo investigations. In this paper, we report effects on a mouse mammary hyperplastic epithelial cell line, TM10, which was exposed to levels of corticosterone that inhibited cell growth in the absence of cytoxicity. This cell line was used because it has been reported that ER may preferentially block the progression of mammary hyperplasias to carcinoma (1). The data obtained, showing a cytostatic effect of corticosterone via perturbations in cell cycle regulators causing a G1 arrest, provide additional evidence for a role of cortical steroid hormones on some but not all of the cellular activities associated with ER-mediated inhibition of mammary carcinogenesis.

MATERIALS AND METHODS

Chemicals. The following materials were purchased from commercial sources: DMEM and F-12 medium, Triton X-100, corticosterone, mifepristone (RU-486), glutaraldehyde, crystal violet, and propidium iodide (Sigma, St. Louis, MO); adult bovine serum (Gemini Bioproducts, Calabasas, CA); insulin and epidermal growth factor (Intergen, Purchase, NY); gentamicin reagent solution (Life Technologies, Inc., Grand Island, NY); anti-cyclin D1, anti-KIP1/P27, and anti-CDK4 antibodies (Neomarkers, Inc., Fremont, CA); goat anti-mouse immunoglobulin-horseradish peroxidase-conjugated secondary antibodies, Rh-GST fusion protein and protein A/G PLUS-agarose beads (Santa Cruz Corp., Santa Cruz, CA); Kip1/p27 antisense oligonucleotides (TriLink BioTechnologies, Inc., San Diego, CA); GSV cytofetin (Glen Research, Sterling, VA); and ECL detection system (Amersham Corp., Arlington Heights, IL).

Cell Culture. The mouse mammary hyperplastic epithelial TM10 cell line was obtained from the laboratory of Medina et al. (13). Cells were grown at 37°C in a humidified incubator with 5% CO\(_2\) in DMEM/F-12 medium (1:1, v/v) containing 2% adult bovine serum, 10 μg/ml gentamicin, 5 ng/ml epidermal growth factor, and 5 μg/ml gentamicin.

Cell Growth Assay. The effect of corticosterone on cell growth was determined by evaluating the number of adherent cells as described previously.

Received 12/5/01; accepted 7/12/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

\(^3\) Supported by United States Public Health Services Grant CA52626 from the National Cancer Institute.

\(^4\) To whom requests for reprints should be addressed, at the Center for Nutrition in the Prevention of Disease, AMC Cancer Research Center, 1600 Pierce Street, Denver, CO 80214. Phone: (303) 239-3436; Fax: (303) 239-3434; E-mail: thompsonh@amc.org.

\(^5\) The abbreviations used are: ER, energy restriction; CKI, cyclin-dependent kinase inhibitor; CDK, cyclin-dependent kinase; Rh, retinoblastoma; ECL, enhanced chemiluminescence; IGF, insulin-like growth factor; FACS, fluorescence-activated cell sorter.
with some modifications. Briefly, ethanol vehicle- or corticosterone-treated TM10 cells were lysed in Rb lysis buffer [50 mM HEPES-KOH (pH 7.5), containing 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 0.1% Tween 20, 10% glycerol, 80 mM β-glycerophosphate, 1 mM sodium fluoride, 0.1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μg/ml leupeptin and aprotinin], and using anticyclin D1 or anti-CDK4 antibody (2 μg) and protein A/G PLUS-agarose beads (20 μl), specific proteins were immunoprecipitated from 200 μg of protein lysate per sample as described above. Beads were washed three times with Rb lysis buffer and then once with Rb kinase assay buffer [50 mM HEPES-KOH (pH 7.5), containing 2.5 mM EGTA, 10 mM β-glycerophosphate, 1 mM sodium fluoride, 0.1 mM sodium orthovanadate, 10 mM MgCl₂, and 1 mM DTT]. Phosphorylation of Rb was measured by incubating the beads with 40 μl of radiolabeled Rb kinase substrate (5 μCi/ml, 32P-ATP, 0.5 μl of 0.1 mM ATP, and 38.75 μl of Rb kinase buffer) for 30 min at 37°C. The reaction was stopped by boiling the samples in SDS sample buffer for 5 min. The samples were analyzed by 12% SDS-PAGE, and the gel was dried and subjected to autoradiography.

Unless specified otherwise, in each case (Western blotting, immunoprecipitation and Western blotting, and kinase assays), only representative gel data are shown from three independent studies. In each study, bands were quantitated by scanning the film with ScanJet (Hewlett Packard, Palo Alto, CA), and the intensity of the bands was analyzed by using the Image-Pro Plus software (Media Cybernetics, Silver Spring, MD). The quantitation bars shown in each case are mean ± SE of three independent studies.

Cell Death Studies. For the studies assessing the effect of corticosterone on cell death, TM10 cells were plated at 1 × 10⁴ cells/60-mm plate as described above. After 24 h, cells were fed with fresh medium and treated with ethanol or various doses of corticosterone (50, 100, or 200 μM) under identical conditions as detailed above. The cultures were fed with fresh medium with ethanol or the same doses of corticosterone every other day up to the end of the experiment. Each treatment and time point had three plates. After 1–3 days of corticosterone treatments, cells were trypsinized and collected. Trypan blue dye exclusion was used to determine cell viability.

To determine apoptotic and necrotic cell death, cells were stained with annexin V and propidium iodide using an apoptosis assay kit (Molecular Probes, Eugene, OR). Briefly, after the above treatments, the collected cells were washed with cold PBS, and 1 × 10⁴ cells were incubated in 100 μl annexin-binding buffer containing 5 μl of annexin V and 1 μl of the 100 μg/ml propidium iodide for 15 min at room temperature. After the incubation period, 400 μl of annexin-binding buffer was added to each sample, mixed gently, and the samples were kept on ice for counting the stained cells by flow cytometry.

Transfection of Kip1/p27 Antisense. The oligonucleotides were purchased from TriLink BioTechnologies, Inc. (San Diego, CA). The antisense oligonucleotide sequence used was 5'-UGG CUC UGC UGG CCA GGC-3' (targets bp 306–320 of murine Kip1) as described previously (19). For the cytofycin procedure, 10 nm oligonucleotides were mixed with GSV cytofycin (2.5 μg/ml; Ref. 19; Glen Research, Sterling, VA) in serum-free medium and incubated for 10 min at 37°C to make an oligonucleotide-cytofycin solution. Logarithmically growing semiconfluent TM10 were cultured in the oligonucleotide-cytofycin solution in complete medium for 24 h. Eighty-five to 90% of exposed cells took up and concentrated the oligonucleotide in the cell nucleus as reflected by uptake of 6-carboxyfluorescein-labeled oligonucleotides determined by fluorescence microscopy.

Blockage of the Glucocorticoid Receptor by RU-486. For the studies assessing the effect of glucocorticoid receptor antagonist, RU-486, and/or corticosterone on cell growth and P27, TM10 cells were treated with either ethanol or 0.1 μM RU-486 and/or 200 μM corticosterone dissolved in ethanol under identical conditions as described above. Each treatment and time point had three plates. After 2 days of treatments, cell number was determined by cell counting using a hemocytometer, and P27 levels in cell lysate were determined by Western blotting as described above.

Statistical Analyses. Differences in the number of TM10 cells after exposure to corticosterone at different doses and time points were evaluated by ANOVA (20). Post hoc comparisons among treatment conditions were made using the Bonferroni multiple range test (20). Data derived from Western blot analyses represent semiquantitative estimates of the amount of a specific protein that is present in a cell extract. This fact was taken into account in the statistical evaluation of the data. The data displayed in the graphs are reported...
RESULTS

Effects of Corticosterone on Cell Growth and Cell Cycle Distribution. In initial range finding experiments, doses of corticosterone ≈25 μM had no effect on cell viability or growth (data not shown). As indicated in Fig. 1A, exposure of TM10 cells to higher concentrations of corticosterone for 24, 48, and 72 h resulted in a statistically significant reduction in cell growth (P < 0.001). Compared with the ethanol control, the magnitude of the reduction was 8, 14, and 25% after 24 h; 43, 51, and 66% after 48 h; and 50, 57, and 76% after 72 h of corticosterone treatments at 50, 100, and 200 μM doses, respectively (Fig. 1A). As shown in Fig. 1B, corticosterone treatment resulted in an insignificant decrease in cell viability measured by trypan blue dye exclusion. Compared with the ethanol-treated control, the percentage of nonviable cells in the total counted cells at 50–200 μM corticosterone was 0.25–1.75% higher after 24 h, 2.5–4.0% higher after 48 h exposure, and 1.5–5.75% higher after 72 h of exposure.

To determine whether cell growth inhibition observed in response to corticosterone treatment was associated with cell cycle arrest, the distribution of cells in different phases of cell cycle was assessed after 24 and 48 h of treatment with 50, 100, and 200 μM doses of corticosterone. As shown in Fig. 1, C and D, FACS analysis of ethanol control and corticosterone-treated TM10 cells clearly indicated a dose-dependent G1 arrest after 24 h of corticosterone treatment, and an additional increase in the G1 population after 48 h of corticosterone treatment at the same doses. The increase in the G1 population was accompanied by a decrease of cells in the S and G2–M phases (Fig. 1, C and D). The cell population in the G1 phase increased with increasing dose of corticosterone, 50, 53, 60, and 66% after 24 h (P < 0.01; Fig. 1C); and 67, 89, 94, and 95% after 48 h (P < 0.01; Fig. 1D) of corticosterone treatments at 0 (ethanol), 50, 100, and 200 μM doses, respectively.

Effect of Corticosterone on Levels of IGF-1 in Medium. Levels of IGF-1 in prepared medium were low (10 ng/ml) and could only be detected in medium that was concentrated. Given that cells in culture often secrete IGF-1 into the medium, the effects of corticosterone on levels of IGF-1 in conditioned medium were assessed. Corticosterone had no effect of levels of IGF-1 in conditioned medium (data not shown).

Effect of Corticosterone on Cell Cycle Regulatory Molecules. Alterations were assessed in cell cycle regulators that might account for the observed inhibition of cell growth and the induction of G1 arrest in cell cycle progression by corticosterone. On the basis of our published in vivo studies showing ER results in lower levels of cyclin D1 and increased levels of KIP1/P27 in rat mammary epithelial cells and tumors (11), attention was focused on the expression of cyclin D1, CDK4, and KIP1/P27, molecules that are also associated with the G1 phase of the cell cycle (21–23). As shown in Fig. 2, corticosterone treatment resulted in a time-dependent decrease in levels of CDK4 and cyclin D1. Compared with ethanol controls, the reduction in CDK4 protein levels was 12, 45, and 92% (P < 0.01; Fig. 2A) and in cyclin D1 was 59, 98, and 84% (P < 0.01; Fig. 2B) after 24, 48, and 72 h of corticosterone treatment at the 200 μM dose, respectively. As shown in Fig. 3, compared with ethanol treated controls, treatment of cells with 50, 100, or 200 μM doses of corticosterone resulted in a significant increase in the levels of KIP1/P27 (P < 0.01). In the dose-response study, 48 h of corticosterone treatment at 50, 100, or
200 μM doses resulted in 4.1, 6.4, and 9.9-fold increase \( (P < 0.01) \) in KIP1/P27 protein levels as compared with vehicle control, respectively (Fig. 3A). Similarly, in the time-response studies, corticosterone treatment at the 200 μM dose for 24, 48, or 72 h resulted in no increase or a 2.5- or 3.9-fold increase \( (P < 0.01) \) in KIP1/P27 levels as compared with control, respectively (Fig. 3B).

**KIP1/P27 Binding with CDK4, and CDK4- and Cyclin D1-associated Kinase Activity.** Because a significant dose- and time-dependent increase in KIP1/P27 was observed after corticosterone treatment, it was next determined whether up-regulation of this CKI exerted an effect on its binding with G1 regulator CDK4 as well as on the kinase activity of CDK4 and associated cyclin D1. As shown by data in Fig. 4, A and B, treatment of TM10 cells with corticosterone for 48 h resulted in a significant decrease, in a dose-dependent manner, of CDK4- (62, 67, and 69% reduction; \( P < 0.01 \)) and cyclin D1- (63, 74, 89% reduction; \( P < 0.01 \)) associated kinase activity. In other studies, as shown in Fig. 4C, the decrease in CDK4 and cyclin D1 kinase activity was found to be associated with a significant increase \( (P < 0.01) \) in the binding of KIP1/P27 to CDK4. The increase started at the 100 μM dose (1.8-fold increase) of corticosterone and was 2.6-fold at the 200 μM dose (Fig. 4C).

**Effects of Kip1/p27 Antisense Oligonucleotide Transfection on Cell Growth and KIP1/P27 Production.** The effect of antisense transfection on cell growth was determined at 24 h after corticosterone treatment. As shown in Fig. 5A, corticosterone-induced inhibition of cell growth was reversed by the transfection of Kip1/p27 antisense oligonucleotides. To determine whether the reversal was associated with depletion of KIP1/P27 protein, the levels of KIP1/P27 protein were determined at 24 and 48 h of corticosterone treatment by Western blotting. As shown in Fig. 5B, the production of KIP1/P27 protein was blocked by transfection of Kip1/p27 antisense oligonucleotides regardless of corticosterone treatment. Compared with TM10 cells without transfection of Kip1/p27 antisense, the levels of KIP1/P27 protein in TM10 cells transfected with Kip1/p27 antisense were reduced by 77% and 79% at 24 and 48 h after treatment with 200 μM corticosterone, respectively. As a positive control, the levels of KIP1/P27 protein in serum-deprived TM10 cells with or without transfection of Kip1/p27 antisense were also examined (Fig. 5B). Compared with TM10 cells without Kip1/p27 antisense transfection, the production of KIP1/P27 protein in Kip1/p27 antisense-transfected TM10 cells was decreased by 87%.

**Effects of RU-486 and/or Corticosterone on Cell Growth and P27.** To determine whether the cytostatic effects of corticosterone were mediated through the glucocorticoid receptor, a glucocorticoid receptor antagonist, RU-486, was used. As shown in Fig. 6A, RU-486 abolished the growth inhibitory activity of corticosterone. Moreover, the increase in cellular levels of P27 that was induced by corticosterone was blocked by concomitant treatment of cells with RU-486 (Fig. 6B).

**Induction of Apoptosis.** On the basis of the data showing that corticosterone inhibited TM10 cell growth, experiments were conducted to determine whether growth inhibition was associated with the induction of either apoptotic or necrotic cell death. This was done by counting annexin-V and propidium iodide-stained cells using FACS analysis. As shown in Fig. 7, A and B, corticosterone treatment of TM10 cells resulted in only mild apoptotic cell death and no
necrotic cell death. Together, these observations suggested that corticosterone treatment of TM10 cells does not result in cytotoxicity via either an apoptotic or necrotic cell death mechanism.

Reversibility of Cell Growth Inhibition. These findings led to the question, "what is the fate of growth-arrested cells?" To answer this question, TM10 cells were treated for 72 h with different doses of corticosterone, and thereafter, corticosterone was removed from the medium and the fold change in cell number per day was monitored for another 72 h. As shown in Fig. 8A and as anticipated, compared with ethanol control, treatment of cells for 72 h with corticosterone resulted in 26, 35, and 54% inhibition of cell growth at 50, 100, or 200 μM doses, respectively. However, when the fold change in cell number per day data were analyzed for 24, 48, and 72 h after the removal of the corticosterone from the medium, as shown by data in Fig. 8B, there was no noticeable difference between different treatments versus ethanol control. Together, these data suggest that the growth inhibitory effect of corticosterone is cytostatic and that the cytostatic effect is reversible when the agent is removed.

DISCUSSION

Our laboratory has reported that ER inhibits the progression of premalignant mammary gland hyperplasias to carcinomas and that the inhibitory activity of ER against mammary carcinomas is correlated with increased adrenal cortical steroid secretion (1). These findings prompted us to determine whether effects on mammary cancer comparable with those induced by ER could be achieved via increasing plasma cortical steroid levels by dietary administration of corticosterone, because as shown in Fig. 6, growth inhibition by corticosterone blocked the glucocorticoid receptor antagonist RU-486. Interestingly, as shown in Fig. 1, A and B, levels of corticosterone between 50 and 200 μM were dose-dependently growth inhibitory without affecting cell viability. Consequently, all of the subsequent studies were done at these concentrations of corticosterone recognizing that whereas these concentrations are considerably higher than physiological levels of exposure observed under ER, our goal was to determine, using an in vitro model system, what cellular and molecular events were induced in mammary epithelial cells that were growth inhibited by noncytotoxic doses of corticosterone in the presence of amounts of serum and growth factors normally used to maintain this cell line.
As shown in Fig. 1, C and D, corticosterone induced a dose- and time-dependent inhibition in the G1 phase of the cell cycle. This observation is consistent with our previous report that ER induces inhibition of cell proliferation in vivo (9). Moreover, it indicates that it is possible to achieve this effect in the absence of concomitant changes in exposure to extracellular growth factors such as IGF-1 because corticosterone treatment had no effect on levels of IGF-1 in the conditioned medium obtained from treated cells. The observation that corticosterone induced a G1 arrest prompted us to focus our investigation on cell cycle regulatory molecules involved in progress through early G1. This decision was made because our in vivo data published previously provided immunohistochemical evidence that ER or dietary administration of corticosterone was associated with a reduction in the percentage of mammary epithelial cells stained positive for KIP1/P27 in animals subjected to ER or fed corticosterone in the diet (11, 12). As shown in Fig. 3, A and B, levels of KIP1/P27 protein were markedly induced by corticosterone treatment thus demonstrat-
levels of KIP1/P27. These findings indicate that induction of KIP1/P27 is essential to growth inhibition by corticosterone. However, because in other systems corticosterone has been reported to exert independent effects on cell cycle progression via the cyclin D1-CDK4 catalytic complex (35), the ability of Kip1/p27 antisense treatment to fully reverse growth inhibition was unanticipated and requires additional investigations, using other model systems and experimental approaches, to define the mechanisms that account for this effect.

The second question addressed in this study was whether corticosterone would induce mammary epithelial cells to undergo apoptosis. On the basis of our in vivo observations of the effects of ER or corticosterone on apoptosis induction in mammary epithelial cells (9, 12), and the reported effects of glucocorticoids on apoptosis induction in other cell types, we predicted that growth inhibition reported in Fig. 1 would be accompanied by induction of apoptosis and possibly secondary necrosis. However, as shown in Fig. 7, such effects were not observed. This finding was unexpected, and it implies that the in vivo effects of ER or corticosterone administration on apoptosis are more likely to be because of the reduction in circulating levels of IGF-1 or some other survival factor(s) that these treatments modulate concomitantly with the change in plasma corticosterone. Thus, it appears that cortical steroids in vitro mimic some but not all of the effects observed in vivo in response to either ER or dietary administration of corticosterone.

The third question investigated in this study was whether the growth inhibitory activity of corticosterone was reversible. Again, based on in vivo evidence and the expectation that corticosterone would induce apoptosis, we hypothesized that growth inhibition...
would be permanent. However, as summarized in Fig. 8, growth inhibition was clearly reversible. Thus, the profound growth inhibitory effects of corticosterone are cytostatic. This implies that, at least from the viewpoint of the action of cortical steroids, the effects of ER in vivo would be reversible. However, given the concomitant effects of ER or dietary administration of corticosterone on other hormones and growth factors, this issue can only be answered via in vivo investigation.

In summary, the results of the present study are consistent with the findings of in vivo studies in which decreased cyclin D1 and increased KIP1/P27 were found in mammary epithelial cells and tumors from animals subjected to ER or administered corticosterone in the diet (11, 12). In the absence of effects on extracellular levels of growth factors like IGF-1, corticosterone inhibited mammary epithelial cell growth and arrested cells in the G1 phase of the cell cycle. These effects were likely because of an increase in intracellular levels of KIP1/P27 with a concomitant reduction in the kinase activity of the CDK4-cyclin D1 catalytic complex. However, unlike the in vivo effects of ER or dietary corticosterone, corticosterone treatment in vitro failed to induce apoptosis. The fact that cell growth inhibition was reversible is consistent with the lack of induction of apoptosis and indicates the need to determine in vivo whether the protective effects of ER against mammary carcinogenesis require sustained restriction of energy intake for inhibitory activity to be maintained.

REFERENCES

Mechanisms of Energy Restriction: Effects of Corticosterone on Cell Growth, Cell Cycle Machinery, and Apoptosis


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/62/18/5280

Cited articles
This article cites 35 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/62/18/5280.full#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/62/18/5280.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/62/18/5280.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.